Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongzhou Lu

Showing results (361-370 of 444) with videos related to

Pageof 45
Sort By:
Australasian Journal on Ageing|October 20, 2021
Risk factors for myocardial injury at admission of 325 patients with coronavirus disease 2019 in Shanghai, ChinaXue Mei, Yuanyuan Ji, Zhiping Qian, et al.
The Lancet Regional Health. Western Pacific|July 24, 2023
Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialFuxiang Wang, Wen Xiao, Yimin Tang, et al.
Emerging Microbes & Infections|January 7, 2025
Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant <i>Serratia marcescens</i>-induced pulmonary infectionXiangke Duan, Wenfeng Liu, Yanyu Xiao, et al.
Annals of Translational Medicine|February 11, 2021
Detection of SARS-CoV-2 in the ocular surface in different phases of COVID-19 patients in Shanghai, ChinaMeiyan Li, Yaling Yang, Taiwen He, et al.
Emerging Microbes & Infections|April 9, 2020
Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trialJun Chen, Rong Chen, Yinzhong Shen, et al.
Emerging Microbes & Infections|August 4, 2021
Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibodyXianmin Meng, Peipei Wang, Yanqing Xiong, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|June 4, 2026
Analysis of the differential clinical characteristics of tuberculosis and nontuberculous mycobacterial diseases among AIDS patientsShuibao Xu, Junyang Yang, Jingna Xun, et al.
Frontiers in Public Health|December 17, 2020
Prediction of COVID-19 Patients at High Risk of Progression to Severe DiseaseZhenyu Dai, Dong Zeng, Dawei Cui, et al.
Antiviral Research|July 12, 2019
Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infectionsHe Yang, Xian Li, Xinyi Yang, et al.
Frontiers in Cellular and Infection Microbiology|November 12, 2019
Characteristics of Gut Microbiota in Patients With Rheumatoid Arthritis in Shanghai, ChinaYang Sun, Qian Chen, Ping Lin, et al.
Pageof 45

Showing results (361-370 of 444) with videos related to

Sort By:
Pageof 45
Australasian Journal on Ageing|October 20, 2021
Risk factors for myocardial injury at admission of 325 patients with coronavirus disease 2019 in Shanghai, ChinaXue Mei, Yuanyuan Ji, Zhiping Qian, et al.
The Lancet Regional Health. Western Pacific|July 24, 2023
Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialFuxiang Wang, Wen Xiao, Yimin Tang, et al.
Emerging Microbes & Infections|January 7, 2025
Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant <i>Serratia marcescens</i>-induced pulmonary infectionXiangke Duan, Wenfeng Liu, Yanyu Xiao, et al.
Annals of Translational Medicine|February 11, 2021
Detection of SARS-CoV-2 in the ocular surface in different phases of COVID-19 patients in Shanghai, ChinaMeiyan Li, Yaling Yang, Taiwen He, et al.
Emerging Microbes & Infections|April 9, 2020
Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trialJun Chen, Rong Chen, Yinzhong Shen, et al.
Emerging Microbes & Infections|August 4, 2021
Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibodyXianmin Meng, Peipei Wang, Yanqing Xiong, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|June 4, 2026
Analysis of the differential clinical characteristics of tuberculosis and nontuberculous mycobacterial diseases among AIDS patientsShuibao Xu, Junyang Yang, Jingna Xun, et al.
Frontiers in Public Health|December 17, 2020
Prediction of COVID-19 Patients at High Risk of Progression to Severe DiseaseZhenyu Dai, Dong Zeng, Dawei Cui, et al.
Antiviral Research|July 12, 2019
Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infectionsHe Yang, Xian Li, Xinyi Yang, et al.
Frontiers in Cellular and Infection Microbiology|November 12, 2019
Characteristics of Gut Microbiota in Patients With Rheumatoid Arthritis in Shanghai, ChinaYang Sun, Qian Chen, Ping Lin, et al.
Pageof 45